|
|
| 222.16 Data as of Apr 17 |  -0.57 / -0.26%Today’s Change | 163.41 Today|||52-Week Range 275.40 | -2.16% Year-to-Date |
The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.
| 4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist Apr 18 / MotleyFool.com |  J&J healthy amid selloffApr 15 / CNNMoney.com |
| The Trader Daily Apr 16 / TheStreet.com | Are Biotechs Bad Medicine for the S&P 500? Apr 15 / MotleyFool.com |
| Biotech Bubble Bust: 2 Ways to Win Apr 15 / MotleyFool.com | 3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana T... Apr 14 / MotleyFool.com |
| 1 month | -13.09% | 3 years | +28.66% | |
| 3 months | -10.26% | 5 years | +28.09% | |
| 1 year | +32.90% | Since inception | +6.38% |
| Previous close | $222.73 |
| Open day’s range | 220.44 – 226.39 |
| Net asset value (NAV) | 222.14 (04/17/2014) |
| Daily volume | 2,970,974 |
| Average volume (3 months) | 2,454,773 |
| IBB | Category | |
|---|---|---|
| Performance 5-yr return | +28.09% | +25.56% |
| Expense Gross exp ratio | 0.48% | 0.43% |
| Risk 5 year sharpe ratio | 1.48 | 1.59 |
| Net assets | $4.9B | $1.3B |
| Average market cap | $13.9B | $31.7B |
| Average P/E | 33.2 | 26.8 |
| Dividend / Share | -- | 0.20% |
| VHT Vanguard Health Care ETF |
| RYH Guggenheim S&P 500® Equal Weight Health... |
| XLV Health Care Select Sector SPDR® Fund |
| Healthcare | 99.91% |
| Business service | 0.09% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| AMGN Amgen Inc | 8.90% |
| BIIB Biogen Idec Inc | 8.04% |
| CELG Celgene Corporation | 7.78% |
| GILD Gilead Sciences Inc | 7.66% |
| ALXN Alexion Pharmaceuticals, Inc. | 6.78% |
| REGN Regeneron Pharmaceuticals, Inc. | 4.04% |
| MYL Mylan Inc | 3.93% |
| VRTX Vertex Pharmaceuticals Inc | 3.92% |
| ILMN Illumina, Inc. | 3.88% |
| BMRN Biomarin Pharmaceutical, Inc. | 2.36% |
.
